NPI: 1104258029 · FAIR LAWN, NJ 07410 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 08/01/2013
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 08/01/2013 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2021 | 1,458 | $42K |
| 2022 | 8,124 | $189K |
| 2023 | 5,466 | $282K |
| 2024 | 2,230 | $168K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | 9,395 | 632 | $677K | |
| A4657 | Syringe, with or without needle, each | 869 | 414 | $3K |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 441 | 178 | $907.50 |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 3,264 | 160 | $0.00 |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 90 | 52 | $0.00 |
| 82728 | 52 | 39 | $0.00 | |
| J1270 | Injection, doxercalciferol, 1 mcg | 928 | 72 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 15 | 14 | $0.00 |
| 83550 | 18 | 14 | $0.00 | |
| 85041 | 159 | 117 | $0.00 | |
| 83970 | 139 | 102 | $0.00 | |
| 85048 | 139 | 105 | $0.00 | |
| J1756 | Injection, iron sucrose, 1 mg | 1,700 | 282 | $0.00 |
| 83540 | 54 | 39 | $0.00 | |
| 90662 | 15 | 13 | $0.00 |